An NCI-designated Comprehensive Cancer Center

Welcome to the Priceman Lab

Priceman Lab Yuki Yamaguchi Pipet
The overarching goal of the research program is to develop chimeric antigen receptor (CAR)-based T cell immunotherapy for the treatment of solid tumors.
Priceman Lab Yuki Yamaguchi Pipet

Saul Priceman, Ph.D., is assistant professor in the Department of Hematology & Hematopoietic Cell Transplantation and associate director of Translational Sciences & Technologies in the T Cell Therapeutics Research Laboratory. Priceman is a principal investigator and provides scientific oversight on solid tumor immunotherapy programs focused on the development of CAR-engineered T cells and rational combination approaches for prostate cancer, breast cancer brain metastasis, ovarian cancer, pancreatic cancer and other solid tumor types.

 

The overarching goal of the research program is to develop chimeric antigen receptor (CAR)-based T cell immunotherapy for the treatment of solid tumors.

 

The lab has primarily been focused on targeting prostate, breast, ovarian and pancreatic cancers. It has recently initiated two phase 1 trials at City of Hope assessing CAR T cell therapy for the treatment of patients with bone metastatic prostate cancer and patients with breast cancer brain metastasis.

 

Critical to successfully translating CAR T cells to patients is understanding and effectively targeting the immunosuppressive tumor microenvironment, which may limit the overall therapeutic potential of adoptive T cell approaches.

 

Therefore, the lab is building more relevant preclinical models to address the challenges facing T cell therapies for solid tumors and to evaluate innovative combination approaches that aim to improve the overall immunotherapy response rates in patients.

Principal Investigator

Saul Priceman, Ph.D.
Assistant Professor, Department of Hematology & Hematopoietic Cell Transplantation
Role: Principal Investigator
Research Focus: Cancer immunotherapy
T cell biology
Immunology

Principal Investigator

Saul Priceman, Ph.D.
Assistant Professor, Department of Hematology & Hematopoietic Cell Transplantation
Role:Principal Investigator
Research Focus: Cancer immunotherapy; T cell biology; Immunology

Lab Members

Research Associate
Staff Scientist
Research Associate
Research Associate
Ph.D. Graduate Student Researcher
Postdoctoral Fellow
Ph.D. Graduate Student Researcher
Research Associate

Alumni

  • Ethan Gerdts, B.S. – now at UCSD in the M.D. program
  • Brook Jeang, M.S. – now at UCI in the Ph.D. program
  • Kelly Kennewick, B.S. – now at UCLA in the Ph.D. program
  • Dileshni Tilakawardane, M.S. – still at City of Hope in T Cell Therapeutics Research Laboratory Regulatory Affairs
  • Anna Kozlowska, Ph.D. – now at Fate Therapeutics in San Diego

Research Support

Current Support
  • Department of Defense
  • California Institute for Regenerative Medicine
  • Prostate Cancer Foundation
  • Kenneth T. and Eileen L. Norris Foundation
  • Meringoff Family Foundation
  • Grateful patients and private donors
Previous Support
  • STOP Cancer Foundation
  • Oxnard Foundation
  • National Comprehensive Cancer Network

Lab Publications

Default publication image
Effective Targeting of TAG72+ Peritoneal Ovarian Tumors via Regional Delivery of CAR-Engineered T Cells. Front Immunol. 2018 Nov 19;9:2268. DOI: 10.3389/fimmu.2018.02268. eCollection 2018.
Murad JP, Kozlowska AK, Lee HJ, Ramamurthy M, Chang WC, Yazaki P, Colcher D, Shively J, Cristea M, Forman SJ, Priceman SJ.
Default publication image
Regional Delivery of Chimeric Antigen Receptor- Engineered T Cells Effectively Targets HER2+ Breast Cancer Metastasis to the Brain. Clinical Cancer Research. 2017. DOI: 10.1158/1078-0432.CCR-17-2041. PubMed PMID: 29061641.
Priceman SJ, Tilakawardane D, Jeang B, Murad JP, Park AK, Chang WC, Ostberg J, Neman J, Jandial R, Portnow J, Forman SJ, Brown CE.
Default publication image
Co-Stimulatory Signaling Determines Tumor Antigen Sensitivity and Persistence of CAR T Cells Targeting PSCA+ Metastatic Prostate Cancer. OncoImmunology. 2017:e1380764. DOI:10.1080/2162402X.2017.1380764.
Priceman SJ, Gerdts E, Tilakawardane D, Kennewick KT, Murad JP, Park AK, Jeang B, Yamaguchi Y, Yang X, Urak R, Weng L, Chang WC, Wright S, Pal SK, Reiter R, Wu AM, Brown CE, Forman SJ.
Default publication image
Targeting Alpha-Fetoprotein (AFP)-MHC Complex with CAR T-Cell Therapy for Liver Cancer. Clinical Cancer Research. 2017 Jan 15;23(2):478-488. DOI: 10.1158/1078-0432.CCR-16-1203. Epub 2016 Aug 17. PubMed PMID: 27535982.
Liu H, Xu Y, Xiang J, Long L, Green S, Yang Z, Zimdahl B, Lu J, Cheng N, Horan LH, Liu B, Yan S, Wang P, Diaz J, Jin L, Nakano Y, Morales JF, Zhang P, Liu LX, Staley BK, Priceman SJ, Brown CE, Forman SJ, Chan VW, Liu C.
Default publication image
Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy. N Engl J Med. 2016 Dec 29;375(26):2561-9. DOI: 10.1056/NEJMoa1610497. PubMed PMID: 28029927; PubMed Central PMCID: PMC5390684.
Brown CE, Alizadeh D, Starr R, Weng L, Wagner JR, Naranjo A, Ostberg JR, Blanchard MS, Kilpatrick J, Simpson J, Kurien A, Priceman SJ, Wang X, Harshbarger TL, D'Apuzzo M, Ressler JA, Jensen MC, Barish ME, Chen M, Portnow J, Forman SJ, Badie B.

In the News

City of Hope is accelerating the development of treatment options for patients with breast cancer who have challenging tumors and poor prognosis with a phase 1 clinical trial that is enrolling patients with refractory HER2-positive breast cancer with brain metastases to test the safety and effectiveness of CAR T cell therapy.
Saul Priceman, Ph.D., and his research team have received a $9.28 million award from the California Institute for Regenerative Medicine to support a CAR T cell phase 1 clinical trial for the treatment of women with HER2-positive breast cancer that has spread to the brain.
Saul Priceman, Ph.D., City of Hope assistant professor in the Department of Hematology & Hematopoietic Cell Transplantation, and his research team have received an award from the California Institute for Regenerative Medicine to support a CAR T cell phase 1 clinical trial for the treatment of women with HER2-positive breast cancer that has spread to the brain.
City of Hope is now enrolling patients in a phase 1 trial evaluating the safety and efficacy of CAR T cell therapy in patients with HER2+ breast cancer that has metastasized to the brain.
A new City of Hope chimeric antigen receptor (CAR) T cell trial – the first to focus on HER2-postive breast cancer patients with brain metastases – is now enrolling potential participants. 
Harnessing the power of CAR T cells
City of Hope’s Stephen J. Forman, M.D., is now an official member of the Parker Institute for Cancer Immunotherapy.
Since 2013, City of Hope researcher Saul Priceman, Ph.D., and his team have developed one of most comprehensive CAR T programs in the nation.
City of Hope’s CAR T research and treatment team is now an official member of the Parker Institute for Cancer Immunotherapy.
In memory of Ben and Beverly Horowitz, longtime chief executive officer and first lady of City of Hope, their family has donated $1 million to City of Hope to help advance groundbreaking CAR-T cell immunotherapy research to combat cancer. 

Lab Location

Saul Priceman Lab
1500 East Duarte Road
Duarte, CA 91010
Ample Free Parking